# Maximus, Inc.: Form 10-Q for the period ended Jun 30, 2018

- Company: [Maximus, Inc.](/companies/mms.md) (CIK 1032220)
- Form: 10-Q
- Filed: 2018-08-09
- Accepted by EDGAR: Aug 9, 2018, 13:49 ET
- Period: 2018-06-30
- Accession: 0001032220-18-000059
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1032220/000103222018000059/mms-2018x06x30x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1032220/000103222018000059/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2018-04-01 to 2018-06-30 | $443.2m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2017-10-01 to 2018-06-30 | $1.38bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2018-04-01 to 2018-06-30 | $154.7m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2017-10-01 to 2018-06-30 | $455.4m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2018-04-01 to 2018-06-30 | $69.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2017-10-01 to 2018-06-30 | $211.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2018-04-01 to 2018-06-30 | $82.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2017-10-01 to 2018-06-30 | $233.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2018-04-01 to 2018-06-30 | $85.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2017-10-01 to 2018-06-30 | $410.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2018-04-01 to 2018-06-30 | $24.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2017-10-01 to 2018-06-30 | $61.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-04-01 to 2018-06-30 | $59.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2017-10-01 to 2018-06-30 | $174.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-04-01 to 2018-06-30 | $0.91 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2017-10-01 to 2018-06-30 | $2.64 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-04-01 to 2018-06-30 | $0.91 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2017-10-01 to 2018-06-30 | $2.65 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-04-01 to 2018-06-30 | 65,925,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2017-10-01 to 2018-06-30 | 66,131,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2017-10-01 to 2018-06-30 | $189.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 9 months, 2017-10-01 to 2018-06-30 | $62.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2018-06-30 | $229.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-06-30 | $739.3m | us-gaap:AssetsCurrent |
| Total assets | at 2018-06-30 | $1.40bn | us-gaap:Assets |
| Current liabilities | at 2018-06-30 | $244.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-06-30 | $345.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2018-06-30 | $1.05bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 42,415 characters.

*The following discussion and analysis of financial condition and results of operations is provided to enhance the understanding of, and should be read in conjunction with, our Consolidated Financial Statements and related Notes included both herein and in our Annual Report on Form 10-K for the year ended September 30, 2017, which was filed with the Securities and Exchange Commission on November 20, 2017.*

### Business Overview

We are a leading operator of government health and human services programs worldwide. We act as a partner to governments under our mission of *Helping Government Serve the People®*. We use our experience, business process management expertise, innovation and technology solutions to help government agencies run effective, efficient and accountable programs.

Our company was founded in 1975 and has grown both organically and through acquisitions. Beginning in 2006, we narrowed our service offerings to focus in the area of business process services (BPS) primarily in the health services and human services markets. In parallel, we divested or exited a number of non-core businesses that fell outside these two areas. Our subsequent growth was driven by the expansion of our health services business around the globe, new welfare-to-work contracts outside the United States and the growth of our business with the U.S. Federal Government. This growth has been both organic and through acquisitions.

Most of our business depends upon government procurement processes. These may be affected, both positively and detrimentally, by changes in administration, the balance of power within a coalition government or legislative body, by the relative priorities of a government and the processes followed by a government in tendering, procuring and awarding contracts. Although we deal with a range of governments, including the federal, state and local governments in the United States and in foreign locations, we are seeing a consistent pattern of procurement delays and project postponements. Such patterns are not unusual and occur from time-to-time, particularly following periods of political, economic or legislative change, including the transition of the Trump administration in the United States, Brexit in the United Kingdom and the current low unemployment levels in many of our geographies which has slowed our welfare-to-work business.

Longer-term, we believe the ongoing demand for our services driven by demographic, economic and legislative trends, coupled with our strong position within our industry, will continue to foster future growth. Our long-term growth thesis is based on the following factors:

- Demographic trends, including increased longevity and more complex health needs, place an increased burden on government social benefit programs. At the same time, programs that address societal needs must be a good use of taxpayer dollars and achieve their intended outcomes. We believe the macro-economic trends of demographics and government needs will continue to drive demand for our services.
- Our contract portfolio offers us excellent revenue visibility. Much of our revenue is derived from long-term contractual arrangements with governments. A contract will often have a base period followed by additional option periods. As a result, single contracts may last several years and client relationships may be decades long. At any time, we are typically able to identify more than 90% of our subsequent twelve months' anticipated revenue from our existing contracts.
- We maintain a strong reputation within the government health and human services industry. Our deep client relationships and reputation for delivering outcomes and creating efficiencies creates a strong barrier to entry in a risk-averse environment. Entering our markets typically requires expertise in complex procurement processes, operation of multi-faceted government programs and an ability to serve and engage with diverse populations.
- We have a portfolio target operating profit margin that ranges between 10% and 15% with high cash conversion, a healthy balance sheet and access to a $400 million credit facility. Our financial flexibility allows us to fund investments in the business, complete strategic mergers and acquisitions to further supplement our core capabilities and seek new adjacent platforms.
- We have an active program to identify potential strategic acquisitions. Our past acquisitions have successfully enabled us to expand our business processes, knowledge and client relationships into adjacent markets and new geographies. Over the past three years, these include:
- In 2017, we acquired Revitalised Limited (Revitalised), a U.K. provider of digital solutions for engaging people in the areas of health, fitness and wellbeing.
- In 2016, we acquired Ascend Management Innovations, LLC (Ascend), a provider of independent, specialized health assessments and data management tools to government agencies in the U.S.
- In 2015, we acquired Assessments Australia, a provider of assessments that identify the support services required to help individuals succeed in a community environment.

### Financial Overview

Our results for the three and nine months ended June 30, 2018, were driven by a number of factors, including:

- Continued growth in our Health Services Segment, including benefits in our third quarter results from change orders tied to work performed in earlier periods, which offset margin declines in certain contracts that were recently renewed or reset;
- Declines in revenue in our U.S. Federal Services Segment, principally due to contracts ending, offset by improved profitability from performance-based contracts;
- In our Human Services Segment, a number of contracts in startup, with associated tempered profit margins, replacing mature contracts;
- Significant income tax benefits resulting from lower U.S. federal tax rates from the Tax Cuts and Jobs Act; and
- The benefit of year-over-year increases in the value of foreign currencies in which we do business, most notably the British Pound.

### Results of Operations

#### Consolidated

The following table sets forth, for the periods indicated, selected statements of operations data:

*(dollars in thousands, except per share data)*

|  | Three Months Ended June 30, 2018 | 2017 | Nine Months Ended June 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Revenue | $597,855 | $600,447 | $1,833,790 | $1,830,058 |
| Cost of revenue | 443,171 | 448,258 | 1,378,343 | 1,380,734 |
| Gross profit | 154,684 | 152,189 | 455,447 | 449,324 |
| Gross profit percentage | 25.9% | 25.3% | 24.8% | 24.6% |
| Selling, general and administrative expenses | 69,588 | 68,308 | 211,706 | 202,302 |
| Selling, general and administrative expense as a percentage of revenue | 11.6% | 11.4% | 11.5% | 11.1% |
| Amortization of intangible assets | 2,525 | 2,720 | 7,846 | 9,508 |
| Restructuring costs | — | — | 2,320 | 2,242 |
| Gain on sale of a business | — | 650 | — | 650 |
| Operating income | 82,571 | 81,811 | 233,575 | 235,922 |
| Operating margin | 13.8% | 13.6% | 12.7% | 12.9% |
| Interest expense | 85 | 458 | 410 | 2,051 |
| Other income, net | 2,249 | 1,306 | 3,928 | 1,986 |
| Income before income taxes | 84,735 | 82,659 | 237,093 | 235,857 |
| Provision for income taxes | 24,493 | 24,871 | 61,793 | 78,643 |
| Effective tax rate | 28.9% | 30.1% | 26.1% | 33.3% |
| Net income | 60,242 | 57,788 | 175,300 | 157,214 |
| Income attributable to noncontrolling interests | 381 | 870 | 856 | 1,117 |
| Net income attributable to MAXIMUS | $59,861 | $56,918 | $174,444 | $156,097 |
| Basic earnings per share attributable to MAXIMUS | $0.91 | $0.87 | $2.65 | $2.38 |
| Diluted earnings per share attributable to MAXIMUS | $0.91 | $0.86 | $2.64 | $2.36 |

As our business segments have different factors driving revenue fluctuations and profitability, the sections that follow cover these segments in greater detail.

Changes in revenue, cost of revenue and gross profit for the three months ended June 30, 2018, are summarized below.

*(dollars in thousands)*

|  | Revenue Dollars | Percentage change | Cost of Revenue Dollars | Percentage change | Gross Profit Dollars | Percentage change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Balance for respective period in fiscal year 2017 | $600,447 |  | $448,258 |  | $152,189 |  |
| Organic effect | (9,328) | (1.6)% | (11,087) | (2.5)% | 1,759 | 1.2% |
| Acquired growth | 376 | 0.1% | 257 | 0.1% | 119 | 0.1% |
| Currency effect compared to the prior period | 6,360 | 1.1% | 5,743 | 1.3% | 617 | 0.4% |
| Balance for respective period in fiscal year 2018 | $597,855 | (0.4)% | $443,171 | (1.1)% | $154,684 | 1.6% |

Revenue for the three months ended June 30, 2018 decreased 0.4% compared to the same period in fiscal year 2017; our cost of revenue decreased by 1.1% for the same period, resulting in an improved profit margin.

We recorded approximately $15.5 million of revenue and operating income from a number of change orders and amendments that were signed during the third quarter but the related costs and work performed occurred in prior periods. Organic revenue growth was partially offset by expected declines in our U.S. Federal Services Segment and Human Services Segment.

Our cost of revenue includes direct costs related to labor, subcontractor labor, outside vendors, rent and other direct costs. Although movements in cost typically correlate with revenue growth, we have experienced profit margin improvements from our U.S. Federal Services Segment due, in part, to higher volumes on performance-based contracts.

Our acquired growth represents the performance of the Revitalised business, which was purchased in July 2017.

The principal driver of the currency effect in both the Health Services and Human Services Segments has been our exposure to the British Pound. During the first nine months of fiscal year 2017, we utilized an average rate of $1.25 to the British Pound; through June 2018, the rate has been closer to $1.36. Our rate in the fourth quarter of fiscal year 2017 was $1.31 to the British Pound; this is broadly comparable with the rate utilized in July 2018.

Changes in revenue, cost of revenue and gross profit for the nine months ended June 30, 2018, are summarized below.

*(dollars in thousands)*

|  | Revenue Dollars | Percentage change | Cost of Revenue Dollars | Percentage change | Gross Profit Dollars | Percentage change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Balance for respective period in fiscal year 2017 | $1,830,058 |  | $1,380,734 |  | $449,324 |  |
| Organic effect | (26,804) | (1.5)% | (27,178) | (2.0)% | 374 | 0.1% |
| Acquired growth | 1,096 | 0.1% | 799 | 0.1% | 297 | 0.1% |
| Currency effect compared to the prior period | 29,440 | 1.6% | 23,988 | 1.7% | 5,452 | 1.2% |
| Balance for respective period in fiscal year 2018 | $1,833,790 | 0.2% | $1,378,343 | (0.2)% | $455,447 | 1.4% |

The factors impacting revenue and cost of revenue for the nine months are similar to those affecting the fiscal quarter.

Selling, general and administrative expense (SG&A) consists of indirect costs related to general management, marketing and administration. It is primarily composed of labor costs. These costs may be incurred at a segment level, for dedicated resources that are not client-facing, or at a corporate level. Corporate costs are allocated to segments on a consistent, rational basis. Fluctuations in our SG&A are driven by changes in our administrative cost base, which is not directly driven by changes in our revenue. As part of our work for the United States Federal Government and many states, we allocate these costs using a methodology driven by the Federal Cost Accounting Standards. During fiscal year 2018, we updated our methodology for allocation of costs which resulted in certain costs which had been within cost of revenue now being classified as SG&A. If we had utilized the same methodology in fiscal year 2018 as we had in fiscal year 2017, we estimate that SG&A would have been lower by approximately $1.0 million and $3.5 million during the three and nine months ended June 30, 2018, respectively. This change in methodology did not affect our operating income.

Amortization charges declined between fiscal years 2017 and 2018. During fiscal year 2017, all intangible assets acquired as part of the Remploy acquisition in 2015 and the technology and trademark assets which were acquired with our acquisition of Policy Studies, Inc. in 2012 were fully amortized. These assets had been amortized at a rate of approximately $3.1 million per year.

During fiscal year 2017, we began restructuring our United Kingdom Human Services operations as part of the ongoing integration of Remploy and to address changes in the employment services market as mainstream employment services programs come to an expected end and government focuses on more specialized health and employment programs supporting people with disabilities and other vulnerable populations. We recorded restructuring costs of $2.2 million for the nine months ended June 30, 2017. During the nine months ended June 30, 2018, we have recorded an additional $2.3 million. This restructuring, principally comprised of severance costs, is expected to result in cost savings in future periods. Remploy is partially owned by its employees and, accordingly, some of this charge is partially offset through a reduction in income attributable to noncontrolling interests.

Overall, our operating income for the three and nine months ended June 30, 2018, increased by 0.9% and decreased by 1.0%, respectively, compared to the same periods last year. Third quarter operating margin received a benefit of $15.5 million of revenue and operating income from the aforementioned change orders, which was partially offset by certain large contracts in the Health Segment that were recently renewed and reset as well as the ongoing ramp-up of new contracts in the startup phase in the Human Services Segment.

Our interest expense is driven by borrowings from our credit facility. During the first half of fiscal year 2017, we were continuing to pay off the debt balance related to our acquisitions of Acentia and Ascend. Our expense during the three and nine months ended June 30, 2018, relates primarily to the cost of maintaining the facility as well as some borrowings to cover short-term working capital needs.

Our other income includes interest income from our cash balances, which we would expect to be small. Our other income from fiscal year 2018 also includes some insurance recoveries; our other income from fiscal year 2017 included interest on research and development tax credits. Neither of these would be expected to recur in future periods.

Our net income for the three and nine months ended June 30, 2018, increased by 4.2% and 12%, compared to the corresponding periods last year. Our net income attributable to MAXIMUS increased by 5.2% and 12%, respectively. These results received a benefit from changes in our tax rates due to the lower U.S. corporate income tax rates as explained below.

#### Income taxes

Our results for the three and nine months ended June 30, 2018, benefited from the estimated effects of the Tax Cuts and Jobs Act (the Act), which was signed on December 22, 2017 and is effective from January 1, 2018. Specifically, our results have been affected by:

- The one-time "toll tax" on undistributed and previously untaxed earnings in foreign locations;
- The one-time benefit from the reduction of our deferred tax liabilities; and
- Reduced U.S. federal income tax rates.

The Act imposes a tax on undistributed earnings of our foreign subsidiaries which were not previously remitted to, or taxed in, the United States. This has been referred to as the “toll tax.” The tax is a combination of two elements; a 15.5% charge for the foreign earnings held in cash and an 8% charge on all other foreign earnings. We can claim a related foreign tax credit for the income taxes paid to a foreign authority. This was an increase to our tax expense.

The Act reduced our statutory tax rate from 35% to 24.5% for fiscal year 2018 and to 21% for future fiscal years. We have deferred tax liabilities within the United States. We recorded a reduction to income tax expense to reflect the favorable impact from the lower income tax rates. In addition, many U.S. states continue to issue their interpretations of the Act, which may change our estimates of our charge. The accounting for certain income tax effects of the Act is provisional. We believe that we have a reasonable basis for our estimates.

The tax reform law in the U.S. improves our after tax cash flows in the U.S. as compared to the prior tax rates and structure and, accordingly, it will improve returns from our U.S. businesses. We estimate that our provision for income taxes for the nine months ended June 30, 2018 was approximately $22.1 million lower as a result of the Act. The net effect of these adjustments resulted in a year-to-date benefit to our effective tax rate of approximately 9.3%. We anticipate that our earnings in the full fiscal year 2018 will receive a benefit of approximately $27.5 million as a consequence of changes in tax legislation from this Act. After considering the impact of U.S. tax reform, our effective income tax rate for fiscal year 2018 is projected to be in the range of 26% to 27%. We anticipate an effective tax rate between 26% and 27% for the fourth fiscal quarter of 2018. The toll tax is payable over eight years and, accordingly, has been recorded as a long-term liability on our balance sheet. We estimate our full year fiscal 2019 effective tax rate will be between 25% and 26%.

Our effective tax rate during the comparative periods was also lower than usual. During the three months ended June 30, 2017, we received a $3.7 million benefit to our income taxes related to research and development tax credits in both the United States and Canada.

During our second and fourth fiscal quarters, we receive the tax benefit from the vesting of restricted stock units (RSUs). The benefit is dependent upon the number of RSUs which vest as well as our share price on the vesting date.

#### Health Services Segment

The Health Services Segment provides a variety of business process services and appeals and assessments for state, provincial and national government programs. These services support a variety of government health benefit programs including Medicaid, the Children's Health Insurance Program (CHIP) and the Affordable Care Act (ACA) in the U.S., Health Insurance BC (British Columbia) in Canada, and the Health Assessment Advisory Service (HAAS) contract in the U.K.

*(dollars in thousands)*

|  | Three Months Ended June 30, 2018 | 2017 | Nine Months Ended June 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Revenue | $359,050 | $335,090 | $1,076,773 | $1,024,813 |
| Cost of revenue | 261,796 | 251,821 | 790,256 | 776,856 |
| Gross profit | 97,254 | 83,269 | 286,517 | 247,957 |
| Operating income | 63,782 | 51,553 | 184,439 | 158,220 |
| Gross profit percentage | 27.1% | 24.8% | 26.6% | 24.2% |
| Operating margin percentage | 17.8% | 15.4% | 17.1% | 15.4% |

Changes in revenue, cost of revenue and gross profit for the three months ended June 30, 2018, are summarized below.

*(dollars in thousands)*

|  | Revenue Dollars | Percentage change | Cost of Revenue Dollars | Percentage change | Gross Profit Dollars | Percentage change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Balance for respective period in fiscal year 2017 | $335,090 |  | $251,821 |  | $83,269 |  |
| Organic effect | 18,814 | 5.6% | 5,435 | 2.2% | 13,379 | 16.1% |
| Acquired growth | 376 | 0.1% | 257 | 0.1% | 119 | 0.1% |
| Currency effect compared to the prior period | 4,770 | 1.4% | 4,283 | 1.7% | 487 | 0.6% |
| Balance for respective period in fiscal year 2018 | $359,050 | 7.2% | $261,796 | 4.0% | $97,254 | 16.8% |

Our revenue for the three month period ended June 30, 2018, increased by 7.2% compared to the same period in fiscal year 2017, driven by organic growth and the effects of currency; cost of revenue increased by 4.0%, resulting in an improvement to our profit margin. On a constant currency basis, our Health Services Segment revenue and cost of revenue grew 5.7% and 2.3%, respectively.

During the third quarter of fiscal year 2018, we received the benefit from approximately $13.7 million of revenue and operating income from a number of contract amendments. These amendments often include expansions in scope and contract terms, but the largest impact in this quarter comes from the reimbursement for work performed in earlier periods. In some instances, we may work at risk and perform services for our customer prior to reaching a final signed agreement on scope and price. Accordingly, although costs have been incurred in prior periods, the corresponding revenue and operating income is not recorded until the change order is signed. As a result, this had a corresponding uplift on our profit margin.

This benefit was partially offset by some declines in our portfolio as contracts were rebid, extended or where option periods were exercised. The contracts have commenced service and are in the early cycles of program and margin maturity. Operating margins are anticipated to be more in-line with the Company's targeted range of 10-15% as these contracts will be in their early stages of maturity into fiscal year 2019.

Changes in revenue, cost of revenue and gross profit for the nine months ended June 30, 2018, are summarized below.

*(dollars in thousands)*

|  | Revenue Dollars | Percentage change | Cost of Revenue Dollars | Percentage change | Gross Profit Dollars | Percentage change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Balance for respective period in fiscal year 2017 | $1,024,813 |  | $776,856 |  | $247,957 |  |
| Organic effect | 30,952 | 3.0% | (3,391) | (0.4)% | 34,343 | 13.9% |
| Acquired growth | 1,096 | 0.1% | 799 | 0.1% | 297 | 0.1% |
| Currency effect compared to the prior period | 19,912 | 1.9% | 15,992 | 2.1% | 3,920 | 1.6% |
| Balance for respective period in fiscal year 2018 | $1,076,773 | 5.1% | $790,256 | 1.7% | $286,517 | 15.6% |

Our revenue for the nine month period ended June 30, 2018 increased by 5.1% compared to the same period in fiscal year 2017. Cost of revenue increased by 1.7%. On a constant currency basis, our Health Services Segment revenue and cost of revenue grew 3.1% and declined 0.3%, respectively.

Our organic growth is driven by increases in scope in existing, mature contracts. These include improvements in our HAAS contract during the year, where we achieved full-year service level targets and the termination of the United Kingdom Fit for Work contract, which provided a short-term profit lift in accelerating deferred revenues and costs as well as the long-term benefit of removing a difficult contract from our portfolio. As we have previously noted, our HAAS contract was extended for two years through February 2020.

#### U.S. Federal Services Segment

The U.S. Federal Services Segment provides business process solutions, program management, as well as system and software development and maintenance services for various U.S. federal civilian programs. The Segment also contains certain state-based assessments and appeals work that is part of the Segment's heritage within the Medicare Appeals portfolio and continues to be managed within this Segment.

*(dollars in thousands)*

|  | Three Months Ended June 30, 2018 | 2017 | Nine Months Ended June 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Revenue | $112,226 | $131,589 | $361,536 | $418,257 |
| Cost of revenue | 79,950 | 97,962 | 268,528 | 310,483 |
| Gross profit | 32,276 | 33,627 | 93,008 | 107,774 |
| Operating income | 14,877 | 15,870 | 41,421 | 51,395 |
| Gross profit percentage | 28.8% | 25.6% | 25.7% | 25.8% |
| Operating margin percentage | 13.3% | 12.1% | 11.5% | 12.3% |

Revenue for the three and nine month periods ended June 30, 2018, decreased by 15% and 14%, compared to the same periods in fiscal year 2017, respectively. The corresponding decline in cost of revenue was 18% and 14%, respectively. All revenue, cost and profit movement between periods is organic. Operating margin expansion for the three months ended June 30, 2018 was due, in part, to higher volumes on a couple of performance-based contracts, including a state-based assessments contract that is more accretive.

Our revenue and costs have declined with the ending of a number of contracts, both those reaching their expected conclusion and some non-recurring, short-term work. Some contract rebids were offered only to small businesses, which precluded us from offering our services. At the end of fiscal year 2017, we had anticipated a benefit from disaster relief efforts; however, in late November 2017, we were informed that these support efforts would be less than we had anticipated.

#### Human Services Segment

The Human Services Segment provides national, state and county human services agencies with a variety of business process services and related consulting services for welfare-to-work, child support, higher education institutions and other human services programs. Approximately 70% of our revenue in this segment was earned in foreign jurisdictions.

*(dollars in thousands)*

|  | Three Months Ended June 30, 2018 | 2017 | Nine Months Ended June 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Revenue | $126,579 | $133,768 | $395,481 | $386,988 |
| Cost of revenue | 101,425 | 98,475 | 319,559 | 293,395 |
| Gross profit | 25,154 | 35,293 | 75,922 | 93,593 |
| Operating income | 7,469 | 16,368 | 18,913 | 37,766 |
| Gross profit percentage | 19.9% | 26.4% | 19.2% | 24.2% |
| Operating margin percentage | 5.9% | 12.2% | 4.8% | 9.8% |

Changes in revenue, cost of revenue and gross profit for the three months ended June 30, 2018, are summarized below.

*(dollars in thousands)*

|  | Revenue Dollars | Percentage change | Cost of Revenue Dollars | Percentage change | Gross Profit Dollars | Percentage change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Balance for respective period in fiscal year 2017 | $133,768 |  | $98,475 |  | $35,293 |  |
| Organic effect | (8,779) | (6.6)% | 1,490 | 1.5% | (10,269) | (29.1)% |
| Currency effect compared to the prior period | 1,590 | 1.2% | 1,460 | 1.5% | 130 | 0.4% |
| Balance for respective period in fiscal year 2018 | $126,579 | (5.4)% | $101,425 | 3.0% | $25,154 | (28.7)% |

Our revenue for the three month period ended June 30, 2018, decreased by 5.4% compared to the same period in fiscal year 2017. The decrease is due to the wind down of several contracts both domestically and internationally, including the Work Programme and the Work Choice contracts in the U.K that are set to end in 2019 as mainstream employment services programs come to an expected end and government focuses on more specialized health and employment programs supporting people with disabilities and other vulnerable populations. Cost of revenue increased by 3.0%. On a constant currency basis, our revenue and cost of revenue declined 6.6% and grew 1.5%, respectively.

Revenue and operating income benefited from a $1.8 million change order that was signed during the third quarter. This was offset by a number of contracts that are in the startup phase and as a group are performing at expectations, but tempering the Segment's financial results as revenue continues to ramp-up based on the progression and accumulation of payments tied to specific program-based outcomes, such as job retention. The Company commenced the new Australian Disability Employment Services Contract on July 1, 2018 and as a result, the Segment is expected to be more severely impacted in the fourth quarter of 2018 by the impacts of new contracts in startup.

Low unemployment rates in many of our geographies have resulted in lower volumes for many of our employment services contracts. Employment services represents the majority of the segment’s portfolio, which has created challenges in maintaining revenue and profit levels. In addition to the low unemployment levels, our government clients are also reshaping how these contracts are structured. As a result, we anticipate mid-single digit operating margin for this segment. In addition, we expect that new contracts which have started or will commence shortly in the second half of the fiscal year will continue to temper margins in the Human Services Segment.

Under existing GAAP, we are required to defer revenue from many of our welfare-to-work contracts until we are certain of earning and collecting these funds, although the work required to reach these milestones may take many months. This typically results in contracts reporting up-front losses. In fiscal year 2019, we will adopt a new revenue recognition standard which, among other things, will allow us to recognize this revenue over the period that we reach each milestone. Although contracts in startup will typically not be as profitable as a mature arrangement, we believe this new revenue recognition methodology will reduce our startup losses.

Changes in revenue, cost of revenue and gross profit for the nine months ended June 30, 2018 are summarized below.

*(dollars in thousands)*

|  | Revenue Dollars | Percentage change | Cost of Revenue Dollars | Percentage change | Gross Profit Dollars | Percentage change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Balance for respective period in fiscal year 2017 | $386,988 |  | $293,395 |  | $93,593 |  |
| Organic effect | (1,035) | (0.3)% | 18,168 | 6.2% | (19,203) | (20.5)% |
| Currency effect compared to the prior period | 9,528 | 2.5% | 7,996 | 2.7% | 1,532 | 1.6% |
| Balance for respective period in fiscal year 2018 | $395,481 | 2.2% | $319,559 | 8.9% | $75,922 | (18.9)% |

Our revenue for the nine month period ended June 30, 2018 increased by 2.2% compared to the same period in fiscal year 2017. Cost of revenue increased by 8.9%. On a constant currency basis, our revenue and cost of revenue declined 0.3% and grew 6.2%, respectively.

The factors impacting revenue and cost of revenue for the nine months are similar to those affecting the fiscal quarter.

### Liquidity and Capital Resources

Our principal source of liquidity remains our cash flows from operations. These cash flows are used to fund our ongoing operations and working capital needs as well as investments in capital infrastructure and our share repurchases. These operating cash flows are driven by our contracts and their payment terms. For many contracts, we are reimbursed for the costs of startup operations, although there may be a gap between incurring and receiving these funds. Other factors which may cause shortfalls in cash flows include contract terms where payments are tied to outcome deliveries, which may not correspond with the costs incurred to achieve these outcomes and short-term delays where government budgets are constrained.

We maintain a credit facility to cover shortfalls in our operating cash flows. We used this facility to fund our acquisitions of Acentia in 2015 and Ascend in 2016, as well as short-term borrowings to cover some immediate working capital needs. At June 30, 2018, we had no borrowings under the credit facility. In September 2017, we extended the life of our credit facility to September 2022, which allows us to borrow up to $400 million, subject to standard covenants. We believe our cash flows from operations should be sufficient to meet our day-to-day requirements for the foreseeable future.

We hold cash balances in foreign locations. Prior to the passage of the Tax Cuts and Jobs Act, these funds could not be used within the United States without incurring an incremental tax charge and, accordingly, we had elected to keep these funds indefinitely reinvested in foreign locations. With the passage of the Act, we have begun moving much of our cash not required for local working capital needs to the U.S.

At June 30, 2018, our cash balances were held in the following locations and denominations:

*(dollars in thousands)*

|  | As of June 30, 2018 |
| --- | ---: |
| U.S. Dollar denominated funds held in the United States | $179,221 |
| U.S. Dollar denominated funds held in foreign locations | 780 |
| Funds held in foreign locations in local currencies | 49,020 |
| Cash and cash equivalents | $229,021 |

20

During July 2018, we remitted approximately $13 million from foreign locations to the United States.

Our priorities for cash utilization remain unchanged.

- We intend to actively pursue new growth opportunities, including strategic acquisitions, business development and investments in technology and innovation to assist organic growth. Our growth opportunities include our commitment to investing in new digital technologies and growing our portfolio of clinical capabilities, including the related people and processes required, to enhance returns in all our businesses.
- We have announced our intention to enhance our quarterly dividend program. Starting in the first quarter of fiscal year 2019, we anticipate increasing our dividend to $0.25 per share each quarter.
- We will continue to make repurchases of our own shares where opportunities arise to do so.

#### Cash Flows

The following table provides a summary of our cash flow information for the nine months ended June 30, 2018 and 2017.

*(dollars in thousands)*

| Net cash provided by/(used in): | Nine Months Ended June 30, 2018 | 2017 |
| --- | ---: | ---: |
| Operations | $189,060 | $252,097 |
| Investing activities | (41,430) | (17,568) |
| Financing activities | (83,478) | (197,636) |
| Effect of exchange rate changes on cash and cash equivalents | (1,383) | 1,286 |
| Net increase in cash and cash equivalents | $62,769 | $38,179 |

Cash flows from operations were $189.1 million for the nine months ended June 30, 2018, compared to $252.1 million in the prior fiscal year. Cash collections from customers in fiscal year 2018 have been reduced due to significant collections in late fiscal year 2017; this decline has been offset by reduced tax payments in the current year.

Our Days Sales Outstanding (DSO) at June 30, 2018 were 66 days; the balance at September 30, 2017 was 63 days. The balance at the beginning of the year was unusually low and included balances which we might have expected to receive during fiscal year 2018, tempering fiscal year 2018 cash flows. Conversely, fiscal year 2017 received the benefit from improved cash collections, reflecting a decline in DSOs. We use the performance indicator of DSO to evaluate our performance in collecting our receivable balances, both billed and unbilled. We have a target range for DSO of 65 to 80 days and we have typically stayed toward the lower end of this range in recent years.

The reduction in our tax rate through the Tax Cuts and Jobs Act resulted in a reduction in cash payments. We continue to anticipate a benefit from these lower rates of approximately $27.5 million in our cash flows from operations and free cash flow.

Cash used in investing activities for the nine months ended June 30, 2018 was $41.4 million compared to $17.6 million in the same period last year. Our cash flows in fiscal year 2018 include some short-term investments.

Cash flows from financing activities in the nine months ended June 30, 2018 included repurchases of our common stock of $62.0 million, compared with $28.9 million in fiscal year 2017. The 2017 fiscal year cash flows also included net debt repayments of $149.9 million.

To supplement our statements of cash flows presented on a GAAP basis, we use the measure of free cash flow to analyze the funds generated from operations.

*(dollars in thousands)*

|  | Nine Months Ended June 30, 2018 | 2017 |
| --- | ---: | ---: |
| Cash flows from operations | $189,060 | $252,097 |
| Purchases of property and equipment and capitalized software costs | (21,552) | (19,088) |
| Free cash flow | $167,508 | $233,009 |

### Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenue and expenses. On an ongoing basis we evaluate our estimates, including those related to revenue recognition and cost estimation on certain contracts, the realizability of goodwill and other long-lived assets, and amounts related to contingencies and income tax liabilities. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.

During the nine months ended June 30, 2018, the passage of the Tax Cuts and Jobs Act has required some additional estimates. With this exception, there were no significant changes to the critical accounting policies we disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Company’s Annual Report on Form 10-K for the year ended September 30, 2017, which was filed with the Securities and Exchange Commission on November 20, 2017.

### Non-GAAP measures

We utilize non‑GAAP measures where we believe it will assist the user of our financial statements in understanding our business. The presentation of these measures is meant to complement, but not replace, other financial measures in this document. The presentation of non-GAAP numbers is not meant to be considered in isolation, nor as an alternative to revenue growth, cash flows from operations or net income as measures of performance. These non-GAAP measures, as determined and presented by us, may not be comparable to related or similarly titled measures presented by other companies.

In fiscal year 2017, 28% of our revenue was generated outside the U.S. We believe that users of our financial statements wish to understand the performance of our foreign operations using a methodology which excludes the effect of year-over-year exchange rate fluctuations. To calculate year-over-year currency movement, we determine the current year’s results for all foreign businesses using the exchange rates in the prior year. We refer to this adjusted revenue on a "constant currency basis."

In recent years, we have made a number of acquisitions. We believe users of our financial statements wish to evaluate the performance of our operations, excluding changes that have arisen due to businesses acquired. We provide organic revenue growth as a useful basis for assessing this. To calculate organic revenue growth, we compare current year revenue excluding revenue from these acquisitions to our prior year revenue.

In order to sustain our cash flows from operations, we require regular refreshing of our fixed assets and technology. We believe that users of our financial statements wish to understand the cash flows that directly correspond with our operations and the investments we must make in those operations using a methodology which combines operating cash flows and capital expenditures. We provide free cash flow to complement our statement of cash flows. Free cash flow shows the effects of the Company’s operations and routine capital expenditures and excludes the cash flow effects of acquisitions, share repurchases, dividend payments and other financing transactions. We have provided a reconciliation of free cash flow to cash provided by operations.

To sustain our operations, our principal source of financing comes from receiving payments from our customers. We believe that users of our financial statements wish to evaluate our efficiency in converting revenue into cash receipts. Accordingly, we provide DSO, which we calculate by dividing billed and unbilled receivable balances at the end of each quarter by revenue per day for the period. Revenue per day for a quarter is determined by dividing total revenue by 91 days.

As noted above, we have access to a $400 million credit facility. Our credit agreement includes the defined term Consolidated EBITDA and our calculation of Adjusted EBITDA conforms to the credit agreement definition. We believe our investors appreciate the opportunity to understand the possible restrictions which arise from our credit agreement. Adjusted EBITDA is also a useful measure of performance which focuses on the cash generating capacity of the business as it excludes the non-cash expenses of depreciation and amortization, and makes for easier comparisons between the operating performance of companies with different capital structures by excluding interest expense and therefore the impacts of financing costs. The measure of Adjusted EBITA is a step in calculating Adjusted EBITDA and facilitates comparisons to similar businesses as it isolates the amortization effect of business combinations. We have provided a reconciliation from net income to Adjusted EBITA and Adjusted EBITDA as follows:

*(dollars in thousands)*

|  | Nine Months Ended June 30, 2018 | 2017 | Trailing Twelve Months Ended June 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net income attributable to MAXIMUS | $174,444 | $156,097 | $227,773 | $206,840 |
| Interest (income)/expense, net | (2,132) | 639 | (2,392) | 1,542 |
| Provision of income taxes | 61,793 | 78,643 | 85,203 | 108,018 |
| Amortization of intangible assets | 7,846 | 9,508 | 10,546 | 12,957 |
| Stock compensation expense | 15,713 | 15,822 | 21,256 | 20,755 |
| Acquisition-related expenses | — | — | 83 | 257 |
| Gain on sale of a business | — | (650) | — | (1,077) |
| Adjusted EBITA | 257,664 | 260,059 | 342,469 | 349,292 |
| Depreciation and amortization of property, plant, equipment and capitalized software | 39,902 | 43,416 | 52,255 | 62,574 |
| Adjusted EBITDA | $297,566 | $303,475 | $394,724 | $411,866 |

23

## Market risk

As filed, 1,464 characters.

Our exposure to market risks generally relates to changes in foreign currency exchange rates.

At June 30, 2018 and September 30, 2017, we held net assets denominated in currencies other than the U.S. Dollar of $133.3 million and $186.8 million, respectively. Of these balances, cash and cash equivalents comprised $49.0 million and $63.7 million, respectively. Accordingly, in the event of a 10% unfavorable exchange rate movement across these currencies, we would have reported the following incremental effects on our comprehensive income and our cash flow statement (in thousands).

|  | June 30, 2018 | September 30, 2017 |
| --- | ---: | ---: |
| Comprehensive income attributable to MAXIMUS | $(13,330) | $(18,680) |
| Net decrease in cash and cash equivalents | 4,902 | 6,367 |

Where possible, we identify surplus funds in foreign locations and place them into entities with the United States Dollar as their functional currency. This mitigates our exposure to foreign currencies. We mitigate our foreign currency exchange risks within our operating divisions through incurring costs and cash outflows in the same currency as our revenue.

We are exposed to interest rate risk through our credit facility when we utilize it. At June 30, 2018, we had no borrowings and therefore, no exposure to interest rate fluctuations. Our interest income will be driven by our use and deployment of funds as well as interest rates in the locations where we hold funds.

## Controls and procedures

As filed, 1,546 characters.

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that these disclosure controls and procedures were effective and designed to ensure that the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(b) Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in connection with the evaluation of our internal control that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 532 characters.

In connection with information set forth in this Form 10-Q, the factors discussed under “Risk Factors” in our Form 10-K for fiscal year ended September 30, 2017 should be considered. The risks included in the Form 10-K could materially and adversely affect our business, financial condition and results of operations. There have been no material changes to the factors discussed in our Annual Report on Form 10-K for the year ended September 30, 2017 which was filed with the Securities and Exchange Commission on November 20, 2017.

Filed Aug 9, 2018.
Source: SEC EDGAR, the filing index for accession 0001032220-18-000059. Last ingested by Listed: Oct 24, 2026, 15:04 ET. No prices; not investment advice.
